Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.77 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.72 |
| ▸ | CTSL | P07711 | 6/20 | 0.72 |
| ▸ | CTSS | P25774 | 3/20 | 0.72 |
| ▸ | CTSB | P07858 | 3/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25406813 | 1.00 | CTSK (0.77) | CTSKCAPN1CTSLCTSSCTSB | |
| SCHEMBL14148467 | 1.00 | CTSK (0.77) | CTSKCAPN1CTSLCTSSCTSB | |
| SCHEMBL2930262 | 1.00 | CTSK (0.77) | CTSKCAPN1CTSLCTSSCTSB | |
| SCHEMBL20770085 | 1.00 | CTSK (0.77) | CTSKCAPN1CTSLCTSSCTSB | |
| SCHEMBL8823918 | 1.00 | CTSK (0.77) | CTSKCAPN1CTSLCTSSCTSB | |
| SCHEMBL7612532 | 0.95 | CTSK (0.71) | CTSKCAPN1CTSLCTSSCTSB | |
| SCHEMBL7612544 | 0.95 | CTSK (0.71) | CTSKCAPN1CTSLCTSSCTSB | |
| SCHEMBL7326845 | 0.95 | CTSK (0.70) | CTSKCAPN1CTSLCTSSCTSB | |
| SCHEMBL1823902 | 0.95 | CTSK (0.76) | CTSKCAPN1CTSLCTSSCTSB | |
| SCHEMBL222158 | 0.95 | CTSK (0.76) | CTSKCAPN1CTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230405124-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF IMMUNE SYSTEM DYSFUNCTION | Oncotracker, Inc. | 2023-12-21 | — | — | US | claimed |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | NOVARTIS AG (CH) | 2026-05-12 | — | — | US | disclosed |
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | NOVARTIS AG (CH) | 2026-02-05 | — | — | US | disclosed |
| US-12275795-B2 | Binding molecules against BCMA and uses thereof | NOVARTIS AG (CH) | 2025-04-15 | — | — | US | disclosed |
| CN-119679936-A | Dosing regimen and combination therapy for multispecific antibodies directed against B cell maturation antigens | 诺华股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-20250090542-A1 | COMBINATION OF A CELL THERAPY AND A GAMMA SECRETASE INHIBITOR | JUNO THERAPEUTICS, INC. (US) | 2025-03-20 | — | — | US | disclosed |
| US-20250034201-A1 | PRODRUGS OF GANAXOLONE | IMMEDICA PHARMA US INC. | 2025-01-30 | — | — | US | disclosed |
| EP-4493574-A1 | PRODRUGS OF GANAXOLONE | Marinus Pharmaceuticals, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-12193994-B2 | Combination of a cell therapy and a gamma secretase inhibitor | JUNO THERAPEUTICS, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| CN-118909952-A | Protein degradation inhibitors for improved production | 隆扎有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-1207095-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 1999-02-03 | — | — | CN | disclosed |
| WO-1997049668-A1 | INHIBITIORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-31 | — | — | WO | disclosed |
| EP-0783489-A1 | ALDEHYDE DERIVATIVES AS UPSTEINE PROTEASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 1997-07-16 | — | — | EP | disclosed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
| WO-1996010014-A1 | ALDEHYDE DERIVATIVES AS UPSTEINE PROTEASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-04 | — | — | WO | disclosed |
| EP-0272671-B1 | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | SANDOZ LTD (CH) | 1994-03-16 | — | — | EP | disclosed |
| US-5158936-A | Treating or prevention of tissue damage, inflammation, bone resporpption and muscular dystrophy | SYNTEX (U.S.A.) INC. (US) | 1992-10-27 | — | — | US | disclosed |
| EP-0209430-B1 | L-DI OR TRIPEPTIDES POSSESSING A BIOLOGICAL ACTIVITY FOR USE IN HUMAN AND VETERINARY MEDICINES, PROCESS FOR THEIR OBTENTION AND MEDICINES CONTAINING THEM | INSTITUT DE RECHERCHES CHIMIQUES ET BIOLOGIQUES APPLIQUEES (I.R.C.E.B.A.) Société à responsabilité limitée dite: (FR) | 1992-06-17 | — | — | EP | disclosed |
| EP-0272671-A2 | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | SANDOZ LTD. (CH) | 1988-06-29 | — | — | EP | disclosed |
| EP-0209430-A2 | L-di or tripeptides possessing a biological activity for use in human and veterinary medicines, process for their obtention and medicines containing them | INSTITUT DE RECHERCHES CHIMIQUES ET BIOLOGIQUES APPLIQUEES (I.R.C.E.B.A.) Société à responsabilité limitée dite: (FR) | 1987-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | BCL9, BRCA1, VCAM1 | CTSK 2322/4885CAPN1 1012/4885CTSL 1092/4885 |
| US-20250034201-A1 | PRODRUGS OF GANAXOLONE | CYP21A2, CYP11B1, CYP11B2 | CTSK 1953/4885CAPN1 1297/4885CTSL 1746/4885 |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | CD2, CD40, CD22 | CTSK 3745/4885CAPN1 3555/4885CTSL 2541/4885 |
| US-12193994-B2 | Combination of a cell therapy and a gamma secretase inhibitor | BACE1, BACE2, GSAP | CTSK 32/4885CAPN1 205/4885CTSL 29/4885 |
| US-12275795-B2 | Binding molecules against BCMA and uses thereof | EPCAM, CD40, BCR | CTSK 2146/4885CAPN1 1985/4885CTSL 1743/4885 |
| US-20250090542-A1 | COMBINATION OF A CELL THERAPY AND A GAMMA SECRETASE INHIBITOR | BACE1, BACE2, GSAP | CTSK 32/4885CAPN1 205/4885CTSL 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.